person · Reporting owner

Reeve Emma

Disclosed activity across 5 companies

Tapewire entity: 38135
SEC CIK: 0001680329

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Editas Medicine, Inc.EDIT · Entity 5502	Director	May 30, 2024	June 03, 2024
PAREXEL INTERNATIONAL CORPPRXL · Entity 172709	Corp. VP & Interim CFO	December 07, 2016	December 09, 2016
PTC THERAPEUTICS, INC.PTCT · Entity 3803	Director	January 02, 2026	January 06, 2026
Whitehawk Therapeutics, Inc.WHWK · Entity 6074	Director	June 12, 2026	June 15, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Editas Medicine, Inc.

Report date May 30, 2024 · Filed June 03, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.17 · Expires 2034-05-29	Direct	25,000	Reported balance After 2024-05-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-05-30 · Grant · Acquired 25,000 · Balance 25,000 F1: This option was granted on May 30, 2024 and is scheduled to vest in full on May 30, 2025

Filing footnotes · ownership attribution and instrument terms

F1: This option was granted on May 30, 2024 and is scheduled to vest in full on May 30, 2025

PAREXEL INTERNATIONAL CORP

Report date December 07, 2016 · Filed December 09, 2016

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	8,468	Reported balance After 2016-12-07 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2016-12-07 · Grant · Acquired 2,348 · Balance 8,468 F1: Shares of restricted stock awarded pursuant to PAREXEL International Corporation 2015 Stock Incentive Plan.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of restricted stock awarded pursuant to PAREXEL International Corporation 2015 Stock Incentive Plan.

PTC THERAPEUTICS, INC.

Report date January 02, 2026 · Filed January 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	10,666	Ending reported balance After 2026-01-05 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2026-01-02 · Grant · Acquired 4,000 · Balance 10,666 F1: Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027. Row 2 · 2026-01-05 · Exercise / conversion · Acquired 734 · Balance 11,400 F2: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. Row 3 · 2026-01-05 · Sale · Disposed 734 · Balance 10,666 F2: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $76.74 · Expires 2036-01-01	Direct	3,475	Reported balance After 2026-01-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-01-02 · Grant · Acquired 3,475 · Balance 3,475 F3: This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.54 · Expires 2035-01-02	Direct	0	Reported balance After 2026-01-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-01-05 · Exercise / conversion · Disposed 734 · Balance 0 F2: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025. F4: Currently exercisable.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027.

F2: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025.

F3: This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026.

F4: Currently exercisable.

Whitehawk Therapeutics, Inc.

Report date June 12, 2026 · Filed June 15, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.16 · Expires 2036-06-12	Direct	38,040	Reported balance After 2026-06-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-12 · Grant · Acquired 38,040 · Balance 38,040 F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CONSTELLATION PHARMACEUTICALS INC

Report date July 15, 2021 · Filed July 19, 2021

Section 16 reporting ended · disclosed 2021-07-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.06	Direct	Reported balance After 2021-07-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-07-15 · Disposition to issuer · Disposed 60,000 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.50	Direct	Reported balance After 2021-07-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-07-15 · Disposition to issuer · Disposed 37,527 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.76	Direct	Reported balance After 2021-07-15 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-07-15 · Disposition to issuer · Disposed 73,428 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.04	Direct	Reported balance After 2021-07-15 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-07-15 · Disposition to issuer · Disposed 11,777 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.60	Direct	Reported balance After 2021-07-15 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-07-15 · Disposition to issuer · Disposed 17,666 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.61	Direct	Reported balance After 2021-07-15 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-07-15 · Disposition to issuer · Disposed 80,971 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.50	Direct	Reported balance After 2021-07-15 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-07-15 · Disposition to issuer · Disposed 66,950 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 01, 2023 Filed Jun 5, 2023 20:30 UTC	Editas Medicine, Inc. EDIT · Entity 5502	GrantStock Option (right to buy) · Derivative	25,000	$0.00 Strike: $9.55	$0.00	Disclosure SEC source: 0001415889-23-009237 · form4-06052023_040625.xml · derivative · entry 1 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-05-31 F1 · derivative.exercise_date: This option was granted on June 1, 2023 and is scheduled to vest in full on June 1, 2024. Read SEC document
May 23, 2023 Filed May 24, 2023 20:12 UTC	PTC THERAPEUTICS, INC. PTCT · Entity 3803	Exercise / conversionStock Option (Right to Buy) · Derivative	1,402	$33.63 Strike: $33.63	$47,149.26	Disclosure SEC source: 0001415889-23-008704 · form4-05242023_080557.xml · derivative · entry 18 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,650 Underlying: Common Stock · 1,402 shares Expires 2028-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. F8 · derivative.exercise_date: Currently exercisable. Read SEC document
May 23, 2023 Filed May 24, 2023 20:12 UTC	PTC THERAPEUTICS, INC. PTCT · Entity 3803	Exercise / conversionStock Option (Right to Buy) · Derivative	1,093	$33.02 Strike: $33.02	$36,090.86	Disclosure SEC source: 0001415889-23-008704 · form4-05242023_080557.xml · derivative · entry 17 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,912 Underlying: Common Stock · 1,093 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. F8 · derivative.exercise_date: Currently exercisable. Read SEC document
May 23, 2023 Filed May 24, 2023 20:12 UTC	PTC THERAPEUTICS, INC. PTCT · Entity 3803	Exercise / conversionStock Option (Right to Buy) · Derivative	157	$33.63 Strike: $33.63	$5,279.91	Disclosure SEC source: 0001415889-23-008704 · form4-05242023_080557.xml · derivative · entry 16 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 837 Underlying: Common Stock · 157 shares Expires 2028-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. F8 · derivative.exercise_date: Currently exercisable. Read SEC document
May 23, 2023 Filed May 24, 2023 20:12 UTC	PTC THERAPEUTICS, INC. PTCT · Entity 3803	SaleCommon Stock	1,402	$59.54	$83,472.00	Disclosure SEC source: 0001415889-23-008704 · form4-05242023_080557.xml · nonDerivative · entry 12 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,200 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. F7 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $59.50 to $59.71 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document
May 23, 2023 Filed May 24, 2023 20:12 UTC	PTC THERAPEUTICS, INC. PTCT · Entity 3803	Exercise / conversionCommon Stock	1,402	$33.63	$47,149.26	Disclosure SEC source: 0001415889-23-008704 · form4-05242023_080557.xml · nonDerivative · entry 11 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,602 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. Read SEC document
May 23, 2023 Filed May 24, 2023 20:12 UTC	PTC THERAPEUTICS, INC. PTCT · Entity 3803	SaleCommon Stock	1,093	$59.53	$65,068.48	Disclosure SEC source: 0001415889-23-008704 · form4-05242023_080557.xml · nonDerivative · entry 10 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,200 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $59.50 to $59.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document
May 23, 2023 Filed May 24, 2023 20:12 UTC	PTC THERAPEUTICS, INC. PTCT · Entity 3803	Exercise / conversionCommon Stock	1,093	$33.02	$36,090.86	Disclosure SEC source: 0001415889-23-008704 · form4-05242023_080557.xml · nonDerivative · entry 9 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. Read SEC document
May 23, 2023 Filed May 24, 2023 20:12 UTC	PTC THERAPEUTICS, INC. PTCT · Entity 3803	SaleCommon Stock	157	$59.52	$9,344.18	Disclosure SEC source: 0001415889-23-008704 · form4-05242023_080557.xml · nonDerivative · entry 8 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,200 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $59.50 to $59.62 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document
May 23, 2023 Filed May 24, 2023 20:12 UTC	PTC THERAPEUTICS, INC. PTCT · Entity 3803	Exercise / conversionCommon Stock	157	$33.63	$5,279.91	Disclosure SEC source: 0001415889-23-008704 · form4-05242023_080557.xml · nonDerivative · entry 7 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. Read SEC document
May 22, 2023 Filed May 24, 2023 20:12 UTC	PTC THERAPEUTICS, INC. PTCT · Entity 3803	Exercise / conversionStock Option (Right to Buy) · Derivative	3,948	$33.63 Strike: $33.63	$132,771.24	Disclosure SEC source: 0001415889-23-008704 · form4-05242023_080557.xml · derivative · entry 15 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,052 Underlying: Common Stock · 3,948 shares Expires 2028-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. F8 · derivative.exercise_date: Currently exercisable. Read SEC document
May 22, 2023 Filed May 24, 2023 20:12 UTC	PTC THERAPEUTICS, INC. PTCT · Entity 3803	Exercise / conversionStock Option (Right to Buy) · Derivative	2,995	$33.02 Strike: $33.02	$98,894.90	Disclosure SEC source: 0001415889-23-008704 · form4-05242023_080557.xml · derivative · entry 14 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,005 Underlying: Common Stock · 2,995 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. F8 · derivative.exercise_date: Currently exercisable. Read SEC document
May 22, 2023 Filed May 24, 2023 20:12 UTC	PTC THERAPEUTICS, INC. PTCT · Entity 3803	Exercise / conversionStock Option (Right to Buy) · Derivative	173	$33.63 Strike: $33.63	$5,817.99	Disclosure SEC source: 0001415889-23-008704 · form4-05242023_080557.xml · derivative · entry 13 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 994 Underlying: Common Stock · 173 shares Expires 2028-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. F8 · derivative.exercise_date: Currently exercisable. Read SEC document
May 22, 2023 Filed May 24, 2023 20:12 UTC	PTC THERAPEUTICS, INC. PTCT · Entity 3803	SaleCommon Stock	3,948	$59.53	$235,029.57	Disclosure SEC source: 0001415889-23-008704 · form4-05242023_080557.xml · nonDerivative · entry 6 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,200 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $59.50 to $59.73 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document
May 22, 2023 Filed May 24, 2023 20:12 UTC	PTC THERAPEUTICS, INC. PTCT · Entity 3803	Exercise / conversionCommon Stock	3,948	$33.63	$132,771.24	Disclosure SEC source: 0001415889-23-008704 · form4-05242023_080557.xml · nonDerivative · entry 5 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. Read SEC document
May 22, 2023 Filed May 24, 2023 20:12 UTC	PTC THERAPEUTICS, INC. PTCT · Entity 3803	SaleCommon Stock	2,995	$59.53	$178,302.83	Disclosure SEC source: 0001415889-23-008704 · form4-05242023_080557.xml · nonDerivative · entry 4 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,200 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $59.50 to $59.73 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document
May 22, 2023 Filed May 24, 2023 20:12 UTC	PTC THERAPEUTICS, INC. PTCT · Entity 3803	Exercise / conversionCommon Stock	2,995	$33.02	$98,894.90	Disclosure SEC source: 0001415889-23-008704 · form4-05242023_080557.xml · nonDerivative · entry 3 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. Read SEC document
May 22, 2023 Filed May 24, 2023 20:12 UTC	PTC THERAPEUTICS, INC. PTCT · Entity 3803	SaleCommon Stock	173	$59.52	$10,297.69	Disclosure SEC source: 0001415889-23-008704 · form4-05242023_080557.xml · nonDerivative · entry 2 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,200 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $59.50 to $59.57 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document
May 22, 2023 Filed May 24, 2023 20:12 UTC	PTC THERAPEUTICS, INC. PTCT · Entity 3803	Exercise / conversionCommon Stock	173	$33.63	$5,817.99	Disclosure SEC source: 0001415889-23-008704 · form4-05242023_080557.xml · nonDerivative · entry 1 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,373 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. Read SEC document
April 21, 2023 Filed Apr 25, 2023 20:08 UTC	PTC THERAPEUTICS, INC. PTCT · Entity 3803	SaleCommon Stock	100	$55.57	$5,557.00	Disclosure SEC source: 0001415889-23-006831 · form4-04252023_080413.xml · nonDerivative · entry 2 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,200 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. Read SEC document
April 21, 2023 Filed Apr 25, 2023 20:08 UTC	PTC THERAPEUTICS, INC. PTCT · Entity 3803	SaleCommon Stock	4,228	$55.04	$232,701.09	Disclosure SEC source: 0001415889-23-006831 · form4-04252023_080413.xml · nonDerivative · entry 1 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,300 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $54.50 to $55.49 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document
January 05, 2023 Filed Jan 9, 2023 21:13 UTC	PTC THERAPEUTICS, INC. PTCT · Entity 3803	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $39.42	$0.00	Disclosure SEC source: 0001415889-23-000671 · form4-01092023_090113.xml · derivative · entry 2 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-01-04 F2 · derivative.exercise_date: This option was granted on January 5, 2023 and vests over one year in twelve equal monthly installments, commencing on February 5, 2023. Read SEC document
January 05, 2023 Filed Jan 9, 2023 21:13 UTC	PTC THERAPEUTICS, INC. PTCT · Entity 3803	GrantCommon Stock	4,000	$0.00	$0.00	Disclosure SEC source: 0001415889-23-000671 · form4-01092023_090113.xml · nonDerivative · entry 1 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,528 F1 · shares: Restricted stock units granted on January 5, 2023 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 6, 2023 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 5, 2024. Read SEC document
June 15, 2022 Filed Jun 17, 2022 20:28 UTC	Whitehawk Therapeutics, Inc. AADI · Entity 6074	GrantStock Option (right to buy) · Derivative	18,573	$0.00 Strike: $13.46	$0.00	Disclosure SEC source: 0001209191-22-037893 · doc4.xml · derivative · entry 1 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,573 Underlying: Common Stock · 18,573 shares Expires 2032-06-15 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of the (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 15, 2022. Read SEC document
June 09, 2022 Filed Jun 13, 2022 20:30 UTC	Editas Medicine, Inc. EDIT · Entity 5502	GrantStock Option (right to buy) · Derivative	25,000	$0.00 Strike: $12.31	$0.00	Disclosure SEC source: 0001415889-22-006493 · form4-06132022_040629.xml · derivative · entry 1 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: This option was granted on June 9, 2022 and is scheduled to vest in full on June 9, 2023. Read SEC document
January 07, 2022 Filed Jan 11, 2022 21:12 UTC	PTC THERAPEUTICS, INC. PTCT · Entity 3803	GrantStock Option (Right To Buy) · Derivative	12,000	$0.00 Strike: $38.10	$0.00	Disclosure SEC source: 0001179110-22-000389 · edgar.xml · derivative · entry 2 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2032-01-06 F2 · derivative.exercise_date: This option was granted on January 7, 2022 and vests over one year in twelve equal monthly installments, commencing on February 7, 2022. Read SEC document
January 07, 2022 Filed Jan 11, 2022 21:12 UTC	PTC THERAPEUTICS, INC. PTCT · Entity 3803	GrantCommon Stock	3,200	$0.00	$0.00	Disclosure SEC source: 0001179110-22-000389 · edgar.xml · nonDerivative · entry 1 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,528 F1 · shares: Restricted stock units granted on January 7, 2022 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 8, 2022 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 7, 2023. Read SEC document
September 08, 2021 Filed Sep 10, 2021 20:47 UTC	Whitehawk Therapeutics, Inc. AADI · Entity 6074	GrantStock option (right to buy) · Derivative	16,486	$0.00 Strike: $27.67	$0.00	Disclosure SEC source: 0000899243-21-035558 · doc4.xml · derivative · entry 1 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,486 Underlying: Common Stock · 16,486 shares Expires 2031-09-08 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, the Initial Award is scheduled to vest as to one thirty-sixth (1/36th) of the shares of common stock subject to the Initial Award on a monthly basis following the grant date on the same day of the month as the grant date (and if there is no corresponding day, on the last day of the month) such that all shares of common stock subject to the Initial Award shall be fully vested on the three year anniversary of the grant date. The grant date is September 8, 2021. Read SEC document
September 03, 2021 Filed Sep 8, 2021 20:33 UTC	Editas Medicine, Inc. EDIT · Entity 5502	GrantStock Option (right to buy) · Derivative	13,736	$0.00 Strike: $68.25	$0.00	Disclosure SEC source: 0001179110-21-008671 · edgar.xml · derivative · entry 1 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,736 Underlying: Common Stock · 13,736 shares Expires 2031-09-02 F1 · derivative.exercise_date: This option was granted on September 3, 2021 and is scheduled to vest over three years in equal yearly installments of one-third of the shares beginning on September 3, 2022 through September 3, 2024. Read SEC document
July 15, 2021 Filed Jul 19, 2021 17:38 UTC	CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050	Disposition to issuerStock Options (Right to buy) · Derivative	66,950	Not disclosed Strike: $35.50	Not disclosed	Disclosure SEC source: 0001562180-21-004984 · primarydocument.xml · derivative · entry 7 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,950 shares Expires not disclosed F1 · price: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). F1 · derivative.exercise_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). F1 · derivative.expiration_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). Read SEC document
July 15, 2021 Filed Jul 19, 2021 17:38 UTC	CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050	Disposition to issuerStock Option (right to buy) · Derivative	80,971	Not disclosed Strike: $6.61	Not disclosed	Disclosure SEC source: 0001562180-21-004984 · primarydocument.xml · derivative · entry 6 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,971 shares Expires not disclosed F1 · price: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). F1 · derivative.exercise_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). F1 · derivative.expiration_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). Read SEC document
July 15, 2021 Filed Jul 19, 2021 17:38 UTC	CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050	Disposition to issuerStock Option (right to buy) · Derivative	17,666	Not disclosed Strike: $7.60	Not disclosed	Disclosure SEC source: 0001562180-21-004984 · primarydocument.xml · derivative · entry 5 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,666 shares Expires not disclosed F1 · price: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). F1 · derivative.exercise_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). F1 · derivative.expiration_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). Read SEC document
July 15, 2021 Filed Jul 19, 2021 17:38 UTC	CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050	Disposition to issuerStock Option (right to buy) · Derivative	11,777	Not disclosed Strike: $8.04	Not disclosed	Disclosure SEC source: 0001562180-21-004984 · primarydocument.xml · derivative · entry 4 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,777 shares Expires not disclosed F1 · price: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). F1 · derivative.exercise_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). F1 · derivative.expiration_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). Read SEC document
July 15, 2021 Filed Jul 19, 2021 17:38 UTC	CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050	Disposition to issuerStock Option (right to buy) · Derivative	73,428	Not disclosed Strike: $8.76	Not disclosed	Disclosure SEC source: 0001562180-21-004984 · primarydocument.xml · derivative · entry 3 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 73,428 shares Expires not disclosed F1 · price: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). F1 · derivative.exercise_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). F1 · derivative.expiration_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). Read SEC document
July 15, 2021 Filed Jul 19, 2021 17:38 UTC	CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050	Disposition to issuerStock Option (right to buy) · Derivative	37,527	Not disclosed Strike: $11.50	Not disclosed	Disclosure SEC source: 0001562180-21-004984 · primarydocument.xml · derivative · entry 2 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,527 shares Expires not disclosed F1 · price: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). F1 · derivative.exercise_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). F1 · derivative.expiration_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). Read SEC document
July 15, 2021 Filed Jul 19, 2021 17:38 UTC	CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050	Disposition to issuerStock Option (Right to Buy) · Derivative	60,000	Not disclosed Strike: $36.06	Not disclosed	Disclosure SEC source: 0001562180-21-004984 · primarydocument.xml · derivative · entry 1 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires not disclosed F1 · price: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). F1 · derivative.exercise_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). F1 · derivative.expiration_date: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). Read SEC document
February 22, 2021 Filed Feb 23, 2021 17:58 UTC	CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050	Exercise / conversionStock Option (right to buy) · Derivative	6,260	$0.00 Strike: $8.04	$0.00	Disclosure SEC source: 0001562180-21-001509 · primarydocument.xml · derivative · entry 6 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,777 Underlying: Common Stock · 6,260 shares Expires 2028-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on April 23, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through April 23, 2022. Read SEC document
February 22, 2021 Filed Feb 23, 2021 17:58 UTC	CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050	SaleCommon Stock	6,260	$37.60	$235,373.50	Disclosure SEC source: 0001562180-21-001509 · primarydocument.xml · nonDerivative · entry 4 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $37.50 to $37.85. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
February 22, 2021 Filed Feb 23, 2021 17:58 UTC	CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050	Exercise / conversionCommon Stock	6,260	$8.04	$50,330.40	Disclosure SEC source: 0001562180-21-001509 · primarydocument.xml · nonDerivative · entry 3 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,260 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 19, 2021 Filed Feb 23, 2021 17:58 UTC	CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050	Exercise / conversionStock Option (right to buy) · Derivative	4,010	$0.00 Strike: $8.04	$0.00	Disclosure SEC source: 0001562180-21-001509 · primarydocument.xml · derivative · entry 5 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,037 Underlying: Common Stock · 4,010 shares Expires 2028-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on April 23, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through April 23, 2022. Read SEC document
February 19, 2021 Filed Feb 23, 2021 17:58 UTC	CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050	SaleCommon Stock	4,010	$37.71	$151,217.90	Disclosure SEC source: 0001562180-21-001509 · primarydocument.xml · nonDerivative · entry 2 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $37.54 to $37.85. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
February 19, 2021 Filed Feb 23, 2021 17:58 UTC	CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050	Exercise / conversionCommon Stock	4,010	$8.04	$32,240.40	Disclosure SEC source: 0001562180-21-001509 · primarydocument.xml · nonDerivative · entry 1 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,010 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 18, 2021 Filed Feb 19, 2021 16:17 UTC	CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050	Exercise / conversionStock Option (right to buy) · Derivative	1,100	$0.00 Strike: $8.04	$0.00	Disclosure SEC source: 0001562180-21-001319 · primarydocument.xml · derivative · entry 6 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,047 Underlying: Common Stock · 1,100 shares Expires 2028-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on April 23, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through April 23, 2022. Read SEC document
February 18, 2021 Filed Feb 19, 2021 16:17 UTC	CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050	SaleCommon Stock	1,100	$37.58	$41,343.06	Disclosure SEC source: 0001562180-21-001319 · primarydocument.xml · nonDerivative · entry 4 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $37.50 to $37.68. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
February 18, 2021 Filed Feb 19, 2021 16:17 UTC	CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050	Exercise / conversionCommon Stock	1,100	$8.04	$8,844.00	Disclosure SEC source: 0001562180-21-001319 · primarydocument.xml · nonDerivative · entry 3 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 17, 2021 Filed Feb 19, 2021 16:17 UTC	CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050	Exercise / conversionStock Option (right to buy) · Derivative	410	$0.00 Strike: $8.04	$0.00	Disclosure SEC source: 0001562180-21-001319 · primarydocument.xml · derivative · entry 5 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,147 Underlying: Common Stock · 410 shares Expires 2028-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on April 23, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through April 23, 2022. Read SEC document
February 17, 2021 Filed Feb 19, 2021 16:17 UTC	CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050	SaleCommon Stock	410	$37.56	$15,397.84	Disclosure SEC source: 0001562180-21-001319 · primarydocument.xml · nonDerivative · entry 2 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $37.50 to $37.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
February 17, 2021 Filed Feb 19, 2021 16:17 UTC	CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050	Exercise / conversionCommon Stock	410	$8.04	$3,296.40	Disclosure SEC source: 0001562180-21-001319 · primarydocument.xml · nonDerivative · entry 1 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 16, 2021 Filed Feb 18, 2021 16:51 UTC	CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050	GrantStock Option (right to buy) · Derivative	66,950	$0.00 Strike: $35.50	$0.00	Disclosure SEC source: 0001562180-21-001261 · primarydocument.xml · derivative · entry 1 Reeve Emma · CIK 0001680329 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,950 Underlying: Common Stock · 66,950 shares Expires 2031-02-15 F1 · derivative.exercise_date: This option was granted on February 16, 2021, and the shares underlying the option vest in equal quarterly installments through February 16, 2025, subject to continued service. Read SEC document
January 06, 2021 Filed Jan 8, 2021 22:10 UTC	PTC THERAPEUTICS, INC. PTCT · Entity 3803	GrantStock Option (Right To Buy) · Derivative	10,000	$0.00 Strike: $66.49	$0.00	Disclosure SEC source: 0001179110-21-000465 · edgar.xml · derivative · entry 2 Reeve Emma · CIK 0001680329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-01-05 F2 · derivative.exercise_date: This option was granted on January 6, 2021 and vests over one year in twelve equal monthly installments, commencing on February 6, 2021. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.